| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shar... |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
WAYNE, Pa., Nov. 5, 2026 – Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company focused on developing therapies targeting the IL-1β pathway for immune-mediated inflammatory diseases, today reported financial re... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
WAYNE, PA., August 6, 2026 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced busi... |
| 23 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 23, 2026, the board of directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Ron Philip to the Board, effective June 23, 2026. |
| 16 Jun 2026 |
8-K: Other Events
ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW June 2026 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.2 |
| 12 Jun 2026 |
8-K: Unregistered Sales of Equity Securities; Material Modification to Rights of Security Holders +2 more
Avalo Therapeutics, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accordance with Sections 141(c) and ... |
| 08 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchas... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
WAYNE, PA, May 13, 2026 — Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business ... |
| 07 May 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Introductory. Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) shares of its common stock, par value $0.001 per share (t... |
| 05 May 2026 |
8-K: Other Events
Abdakibart (AVTX-009) in Moderate-to-Severe Hidradenitis Suppurativa Positive Topline Results from the Phase 2 LOTUS Study May 2026 | AVALO THERAPEUTICS, INC. (AVTX) 1 Exhibit 99.2 |
| 28 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This Milestone Buyout Option Agreement and Amendment to the Agreement and Plan of Merger and Reorganization (this “Amendment”) is made as of April 26, 2026 (the “Amendment Date”), by and between Avalo Therapeutics, Inc., a Delaware corpo... |
| 27 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 23, 2026, Dr. Jonathan Goldman and Mitchell Chan, members of the board of directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”), each notified the Company of his decision to not stand for re-election to the Board a... |
| 23 Mar 2026 |
8-K: Results of Operations and Financial Condition
WAYNE, PA, March 23, 2026 — Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced busines... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Other Events
ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW January 2026 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1 |
| 02 Dec 2025 |
8-K: Other Events
ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW December 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1 |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
WAYNE, PA, November 6, 2025 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business update... |
| 29 Oct 2025 |
8-K: Other Events
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa |
| 10 Oct 2025 |
8-K: Other Events
ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW OCTOBER 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1 |
| 01 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
On behalf of Avalo Therapeutics, Inc., a Delaware corporation (the “Company”), we are pleased to formalize for you the terms of your employment with the Company as set forth in this agreement (the “Agreement”). |
| 22 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
WAYNE, PA., September 22, 2025 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointm... |
Loading...